Compare Regeneron Pharmaceuticals Inc (REGN) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Utilities Select Sector SPDR Fund — how do they compare? Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B), while Utilities Select Sector SPDR Fund trades at $41.19 (market cap $23.28B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.3× Utilities Select Sector SPDR Fund's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Utilities Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Utilities Select Sector SPDR Fund for 80 Days on average.
| REGN | XLU | |
|---|---|---|
Market Cap | $76.40B | $23.28B |
Volume | 626,381 | 44,925,171 |
Sector | Health | — |
52-Week High | $852.03 | $47.73 |
52-Week Low | $557.73 | $39.25 |
Typical Hold Time | 107 Days | 80 Days |
Enterprise Value | $71.12B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
XLU, the Utilities Select Sector SPDR ETF, trades at $41.15, down 0.02% on the day, and is near recent lows amid sector-wide pressure from rising interest rates. Technical indicators show a mixed but overall bullish signal, with moving averages bullish and oscillators neutral. The ETF recently hit a 52-week low, reflecting investor concerns over utility stocks as defensive plays in a higher-rate environment. News highlights oversold conditions and debates over AI-driven power demand versus regulatory hurdles.
Outlook remains cautious; while oversold conditions may attract contrarian buyers, persistent rate hikes and regulatory freezes on data centers pose headwinds. The dividend yield offers income, but sector volatility requires careful risk management amid macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
